Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biocept Inc (BIOC)

Biocept Inc (BIOC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 71,808
  • Shares Outstanding, K 13,397
  • Annual Sales, $ 5,530 K
  • Annual Income, $ -25,140 K
  • 60-Month Beta 0.86
  • Price/Sales 5.36
  • Price/Cash Flow N/A
  • Price/Book 3.44
Trade BIOC with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.00
  • Growth Rate Est. (year over year) +50,050.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.35 +23.22%
on 01/04/21
5.74 -6.62%
on 01/15/21
+0.08 (+1.52%)
since 12/15/20
3-Month
4.11 +30.41%
on 10/28/20
6.35 -15.59%
on 11/12/20
+0.60 (+12.61%)
since 10/15/20
52-Week
2.11 +153.79%
on 03/17/20
13.00 -58.77%
on 08/06/20
+1.77 (+49.22%)
since 01/15/20

Most Recent Stories

More News
Biocept Issues Letter to Stockholders

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO...

BIOC : 5.36 (-2.19%)
Meridian Bioscience to Participate in H. C. Wainright Bioconnect 2021 Virtual Conference

Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference....

BIOC : 5.36 (-2.19%)
CDNA : 88.15 (+1.52%)
VIVO : 21.59 (-2.44%)
Biocept to Present at H.C. Wainwright Virtual BioConnect Conference

, /PRNewswire/ -- . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve...

BIOC : 5.36 (-2.19%)
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

, /PRNewswire/ --Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information...

BIOC : 5.36 (-2.19%)
Biocept Enters into Laboratory Services Agreements with Two Southern California Regional Independent Physician Associations

, /PRNewswire/ --  (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve...

BIOC : 5.36 (-2.19%)
Global E-Clinical Solution Software Market Will Reach USD 10.9 Billion by 2026: Facts & Factors

Facts and Factors have published a new research report titled "E-Clinical Solution Software Market By Product (Electronic Trial Master Files, Electronic Data Capture and Clinical Data Management Systems,...

BIOC : 5.36 (-2.19%)
DTRK : 5.8500 (+22.13%)
MDSO : 92.22 (-0.02%)
MRGE : 0.2490 (-0.40%)
Global Liquid Biopsy Market to Grow by $4.02 Billion During 2020-2024 | Featuring ANGLE Plc, Biocept Inc., and Bio-Techne Corp. Among Others | Technavio

Technavio estimates the global liquid biopsy market is expected to grow by USD 4.02 billion, progressing at a CAGR of almost 38% during the forecast period. The report offers an up-to-date analysis regarding...

ANPCY : 8.2500 (unch)
BIOC : 5.36 (-2.19%)
Biocept Provides Business Update

, /PRNewswire/ -- . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve...

BIOC : 5.36 (-2.19%)
Biocept's Target Selector™ Liquid Biopsy Demonstrated High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

, /PRNewswire/ -- . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve...

BIOC : 5.36 (-2.19%)
Prostate Cancer Diagnostics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The research report on Prostate Cancer Diagnostics provide insights on growth-influencing factors such as industry trends, understanding consumer demands, product application, competitive landscape, pricing...

DXD.VN : 0.040 (unch)
A : 126.21 (+0.14%)
BIOC : 5.36 (-2.19%)
CGIX : 3.18 (+0.63%)
FMI : 136.95 (-0.04%)
GHDX : 63.44 (-0.69%)
OPK : 4.55 (+0.66%)
SIEGY : 72.3800 (-2.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept,...

See More

Key Turning Points

3rd Resistance Point 6.07
2nd Resistance Point 5.91
1st Resistance Point 5.63
Last Price 5.36
1st Support Level 5.19
2nd Support Level 5.03
3rd Support Level 4.75

See More

52-Week High 13.00
Fibonacci 61.8% 8.84
Fibonacci 50% 7.56
Fibonacci 38.2% 6.27
Last Price 5.36
52-Week Low 2.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar